Duration of Treatment in Monoclonal Antibody Trials

The Trailblazer All2 study is innovative in its approach to treating patients with monoclonal antibodies. Instead of indefinitely treating patients, the study titrated the duration of treatment based on PET scans. If patients showed cleared amyloid plaques, they were transitioned to placebo. This limited duration treatment approach makes it more feasible and cost-effective for our healthcare system.